AgomAb Therapeutics NV (AGMB) Balance Sheet
AGMB balance sheet, 2025
December 31, 2025 · euros€153.7M assets = €22.8M liabilities + €130.9M equity
Both columns are drawn to the same scale: what AGMB owns equals what it owes plus shareholders’ equity. Hover a block for its value.
AGMB financial health
Descriptive bands, not a rating. Fiscal 2025.
AGMB balance sheet trends, 2021–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | €84.0M2021 | €153.7M2025 | +16.3%/yr | |
| Total liabilities | €41.6M2021 | €22.8M2025 | −14.0%/yr | |
| Shareholders’ equity | €42.4M2021 | €130.9M2025 | +32.6%/yr | |
| Cash & short-term investments | €53.6M2021 | €116.5M2025 | +21.4%/yr | |
| Total debt | €690,0002021 | €1.3M2025 | +16.1%/yr | |
| Net cash (debt) | €52.9M2021 | €115.3M2025 | +€62.4M | |
| Working capital | €20.7M2021 | €102.6M2025 | +€81.9M | |
| Current ratio | 1.612021 | 6.522025 | +4.91 | |
| Debt / equity | 0.022021 | 0.012025 | −0.01 | |
| Shares outstanding | 36.2M2022 | 48.7M2025 | +10.4%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
AGMB assets
AGMB liabilities and equity
AGMB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
AGMB balance sheet in euros
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & short-term investments | €116.5M | €171.5M | €122.4M | €67.7M | €53.6M |
| Cash & equivalents | €86.4M | €171.5M | €122.4M | €27.7M | €53.6M |
| Short-term investments | €30.1M | €0 | €0 | €40.0M | €0 |
| Receivables | €4.8M | €0 | €0 | €0 | €0 |
| Inventory | €0 | €0 | €0 | €0 | €0 |
| Other current assets | €0 | €2.4M | €17.1M | €3.4M | €841,000 |
| Total current assets | €121.2M | €173.8M | €139.5M | €71.1M | €54.4M |
| Property, plant & equipment (net) | €1.6M | €2.0M | €1.6M | €62,000 | €0 |
| Goodwill & intangible assets | €33.7M | €28.7M | €28.7M | €28.7M | €28.7M |
| Long-term investments | €11,000 | €12,000 | €14,000 | €14,000 | €147,000 |
| Other non-current assets | €0 | €1.8M | €1.4M | €1.1M | €698,000 |
| Total assets | €153.7M | €206.4M | €171.3M | €101.0M | €84.0M |
| Liabilities | |||||
| Accounts payable | €7.6M | €6.0M | €6.8M | €3.9M | €1.1M |
| Short-term debt | €249,000 | — | — | — | — |
| Deferred revenue | €1.5M | — | — | — | — |
| Total current liabilities | €18.6M | €9.1M | €10.9M | €29.7M | €33.7M |
| Long-term debt | €0 | €0 | €0 | €0 | €690,000 |
| Lease obligations | €1.3M | €1.5M | €1.6M | €62,000 | €0 |
| Other long-term liabilities | €4.2M | €9.2M | €8.9M | €5.0M | €7.2M |
| Total liabilities | €22.8M | €18.3M | €19.8M | €34.7M | €41.6M |
| Shareholders' equity | |||||
| Common stock & paid-in capital | €223.1M | — | — | — | — |
| Retained earnings (deficit) | −€181.7M | −€119.2M | −€72.8M | −€61.4M | −€44.8M |
| Accumulated other comprehensive income | −€967,000 | — | — | — | — |
| Total shareholders' equity | €130.9M | €188.1M | €151.4M | €66.2M | €42.4M |
| Key figures | |||||
| Total debt | €1.3M | — | — | — | €690,000 |
| Net cash (debt) | €115.3M | — | — | — | €52.9M |
| Working capital | €102.6M | €164.7M | €128.6M | €41.4M | €20.7M |
| Tangible book value | €97.2M | €159.4M | €122.7M | €37.5M | €13.6M |
| Shares outstanding | 48.7M | 36.2M | 36.2M | 36.2M | — |
| Current ratio | 6.52 | 19.05 | 12.81 | 2.39 | 1.61 |
| Quick ratio | 6.53 | 18.79 | 11.25 | 2.28 | 1.59 |
| Debt / equity | 0.01 | — | — | — | 0.02 |
| Equity / assets | 85.2% | 91.1% | 88.4% | 65.6% | 50.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Dec '24 | |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & short-term investments | €252.0M | €129.6M | €116.5M | €129.6M | €171.5M |
| Cash & equivalents | €221.6M | €129.6M | €86.4M | €129.6M | €171.5M |
| Short-term investments | €30.4M | — | €30.1M | — | €0 |
| Receivables | €0 | €2.1M | €4.1M | €0 | €2.1M |
| Inventory | €0 | €0 | €0 | €0 | €0 |
| Other current assets | €6.5M | €1.3M | €638,000 | €3.4M | €267,000 |
| Total current assets | €258.5M | €133.0M | €121.2M | €133.0M | €173.8M |
| Property, plant & equipment (net) | €1.4M | €1.7M | €1.6M | €1.7M | €2.0M |
| Goodwill & intangible assets | €28.7M | €28.7M | €28.7M | €28.7M | €28.7M |
| Long-term investments | €13,000 | €0 | €11,000 | €11,000 | €12,000 |
| Other non-current assets | €2.3M | €2.2M | €2.1M | €2.2M | €1.8M |
| Total assets | €290.9M | €165.6M | €153.7M | €165.6M | €206.4M |
| Liabilities | |||||
| Accounts payable | €11.8M | €7.6M | €7.6M | €7.6M | €6.0M |
| Short-term debt | €229,000 | €242,000 | €249,000 | €242,000 | €273,000 |
| Deferred revenue | €1.3M | €1.7M | €1.5M | €1.7M | €801,000 |
| Total current liabilities | €20.1M | €9.5M | €18.6M | €9.5M | €9.1M |
| Long-term debt | €0 | €0 | €0 | €0 | €0 |
| Lease obligations | €1.1M | — | €1.3M | €1.3M | €1.5M |
| Other long-term liabilities | €5.5M | €9.2M | €4.2M | €9.2M | €9.2M |
| Total liabilities | €25.5M | €18.7M | €22.8M | €18.7M | €18.3M |
| Shareholders' equity | |||||
| Common stock & paid-in capital | €304.6M | €223.1M | €223.1M | €223.1M | €223.1M |
| Retained earnings (deficit) | −€212.6M | −€164.3M | −€181.7M | −€164.3M | −€119.2M |
| Accumulated other comprehensive income | −€14.4M | −€966,000 | −€967,000 | −€966,000 | −€966,000 |
| Total shareholders' equity | €265.4M | €146.9M | €130.9M | €146.9M | €188.1M |
| Key figures | |||||
| Total debt | €1.1M | €1.3M | €1.3M | €1.3M | €1.5M |
| Net cash (debt) | €250.8M | €128.3M | €115.3M | €128.3M | €169.9M |
| Working capital | €238.4M | €123.5M | €102.6M | €123.5M | €164.7M |
| Tangible book value | €236.7M | €118.2M | €102.2M | €118.2M | €159.4M |
| Shares outstanding | 49.2M | 36.2M | 48.7M | 42.5M | 36.2M |
| Current ratio | 12.88 | 13.99 | 6.52 | 13.99 | 19.05 |
| Quick ratio | 12.55 | 13.85 | 6.49 | 13.63 | 19.02 |
| Debt / equity | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
| Equity / assets | 91.2% | 88.7% | 85.2% | 88.7% | 91.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported (latest annual report filed December 31, 2025); data from EODHD.
AGMB financial position
At the end of fiscal 2025 (December 31, 2025), AgomAb Therapeutics NV had total assets of €153.7 million (down 25.5% from a year earlier), total liabilities of €22.8 million and shareholders' equity of €130.9 million. It held €116.5 million in cash and short-term investments against €1.3 million of debt, a net cash position of €115.3 million. Its current ratio was 6.52. In the latest quarter (ended June 30, 2026) total assets were €290.9 million and equity €265.4 million.
Related: AGMB income statement, AGMB cash flow statement, AGMB key metrics. See the AGMB stock overview for the latest quote and news.
AGMB balance sheet FAQ
What are AgomAb Therapeutics NV's total assets?
AgomAb Therapeutics NV reported total assets of €153.7 million at the end of fiscal 2025 (December 31, 2025), compared with €206.4 million a year earlier.
How much debt does AgomAb Therapeutics NV have?
AgomAb Therapeutics NV had €1.3 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.01.
How much cash does AgomAb Therapeutics NV have?
AgomAb Therapeutics NV held €116.5 million in cash and short-term investments at the end of fiscal 2025; with €1.3 million of debt that is net cash of €115.3 million.
What is AgomAb Therapeutics NV's book value?
AgomAb Therapeutics NV's shareholders' equity (book value) was €130.9 million at the end of fiscal 2025.
What is AgomAb Therapeutics NV's current ratio?
AgomAb Therapeutics NV had current assets of €121.2 million and current liabilities of €18.6 million, a current ratio of 6.52 (it can cover its short-term obligations).
How much goodwill does AgomAb Therapeutics NV have?
AgomAb Therapeutics NV carried €33.7 million of goodwill and intangible assets, 21.9% of total assets, at the end of fiscal 2025.